{
  "docId": "019de073-7953-75ff-b7a7-421adee0c76c",
  "docSlug": "f2ba5faea717d1fc1a89b119873b0327",
  "documentTitle": "Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides",
  "authorId": "anebulo-pharmaceuticals",
  "authorName": "Anebulo Pharmaceuticals",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 42,
  "pageCount": 53,
  "prevPage": 41,
  "nextPage": 43,
  "slideType": "other",
  "function": "present_framework",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "Clinical trial update slide.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de073-7953-75ff-b7a7-421adee0c76c/42",
  "deckHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c",
  "deckJsonHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c.json",
  "deckAnchorHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c#slide-42",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.8,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "Protocol amended to allow staggered dosing and add additional time points/subjective measures\nCohort 3: staggered single oral doses of 21 mg oral THC and 10 mg ANEB-001 or placebo\nTHC will be administered 1 hour before ANEB-001/placebo\nStudy endpoints include all of those assessed in Part A\nNew “post-THC baseline” assessments added prior to administration of ANEB-001\nAllows for evaluation of within subject changes\nNew “drug effect” VAS scores added\nProtocol details will be posted in the clinicaltrials.gov record\nProtocol includes 6 cohorts in total for Part B",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e3adc8f-20b3-417c-8f4f-7f442d046957",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Part B Cohort 3 - Protocol Amended and Dosing Initiated",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b58a470-a3d9-4145-9ec0-0293f870c907",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "0bd8930c-c37b-454a-9e2c-b4a238406998",
      "evidence": "The slide contains a list/bullet point component.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 48,
      "from": 13,
      "beatId": "684e64de-8d19-434b-83aa-4bfe1e4eb804",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 13-48 present ANEB-001 as a solution, detailing its pharmacology, clinical trial results, and development plan.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}